Surgery may boost survival in rare artery disease
NCT ID NCT07149805
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at 78 people with Takayasu arteritis, a rare disease that causes narrowing of the main artery from the heart. Researchers compared those who had surgery or a procedure to open the artery with those who got only medication. The goal was to see which group lived longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If surgery proves better, it could guide doctors to recommend it more often for severe cases, potentially improving survival.
- What could go wrong
- This is a small, retrospective study, not a controlled trial. Results may not apply to all patients, and surgery carries its own risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TAKAYASU ARTERITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Rare artery disease linked to higher heart attack and stroke risk
- New Total-Body PET scanner could revolutionize vasculitis diagnosis
- 5,000 patients to help unlock secrets of inflammatory heart disease
- New hope for rare artery disease? small trial tests upadacitinib
- Hope for takayasu patients: study tests stopping biologic drugs after years of remission